Clinical trials: Moderate to Severe Chronic Obstructive Pulmonary Disease
- Condition Moderate to Severe Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
Chronic Obstructive Pulmonary Disease
A Study to Assess the Long-term Safety of QVA149
The study is designed to provide long-term safety data for QVA149 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- ENLIGHTEN (NCT01120717)
- Testing
- QVA149
- Where
- 53 sites in Canada, France and 8 more
- Volunteers
- 339 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary aim of this study is to investigate the tolerability and safety of AZD 1236 compared with placebo ("inactive substance") in COPD patients by assessment of Adverse Events, vital signs and laboratory safety assessments.
- Trial name
- CERA (NCT00758459)
- Testing
- AZD1236
- Where
- 14 sites in Bulgaria, Finland and 3 more
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema
PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The objective of the present study is to establish the safety and efficacy of multiple administrations of Prochymal™(ex-vivo cultured human adult mesenchymal stem cells) in participants with moderate to severe chronic obstructive…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
- Trial name
- NCT00683722
- Testing
- Prochymal™
- Where
- 6 sites in United States
- Volunteers
- 62 people
- Sponsor
- Mesoblast, Inc.
Pulmonary Disease, Chronic Obstructive
To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)
The study will be conducted in a single-center, randomized, single-blinded, placebo-controlled, dose escalation design with two dose groups.Multiple-dose inhalation of Ciprofloxacin inhale 50 and 75 mg or placebo will be…
- Trial name
- NCT01072942
- Testing
- Ciprofloxacin (Cipro InhaIe, BAYQ3939)
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease
Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects
A clinical trial to investigate the pharmacokinetics, safety and tolerability of CHF6001 after single administrations in participants with mild, moderate and severe liver impairment with matched healthy adult volunteers
- Trial name
- NCT05373953
- Testing
- CHF6001
- Where
- Bulgaria
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
COPD
A Study to Investigate Using Inhaled Fexlamose to Treat Adult Participants Who Have Moderate to Severe COPD
AER-01-002 is a Phase 2a study being conducted to determine if inhaled fexlamose is an effective and safe treatment for adults with moderate to severe COPD. Study will compare active drug to placebo.
- Trial name
- AER-01-002 (NCT06731959)
- Testing
- Flexlamose
- Volunteers
- 100 people
- Sponsor
- Aer Therapeutics
Chronic Bronchitis
RejuvenAir® System Trial for COPD With Chronic Bronchitis
Chronic Obstructive Pulmonary Disease (COPD) is defined as an impaired ability to move air within the lungs and is a major public health problem that is projected to rank fifth worldwide in terms of disease burden and third in…
- Trial name
- SPRAY-CB (NCT03893370)
- Testing
- RejuvenAir System
- Where
- 27 sites in United States, United Kingdom
- Volunteers
- 210 people
- Sponsor
- CSA Medical, Inc.
Pulmonary Disease, Chronic Obstructive
Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This exploratory study will compare the efficacy of the fixed-dose combination (FDC) of aclidinium bromide and formoterol fumarate once daily in the morning and placebo once in the evening vs.
- Trial name
- NCT00706914
- Testing
- Once-daily aclidinium/formoterol, Twice-daily formoterol fumarate, Once-daily formoterol fumarate
- Where
- 40 sites in United States
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary aim of this study is to investigate the effects of AZD1236 compared with placebo ("inactive substance") in COPD patients by analysing biomarkers for inflammation and tissue degradation in blood, urine and sputum.
- Trial name
- BICO (NCT00758706)
- Testing
- AZD1236
- Where
- 10 sites in Denmark, Finland and 2 more
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Psoriasis
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at…
- Trial name
- NCT01186744
- Testing
- CP-690,550
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death.
- Trial name
- iCHOROS (NCT07069829)
- Where
- 36 sites in Argentina, Colombia and 10 more
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Chronic, Non Malignant Pain
Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain
Two stage study looking at different titration schedules in patients with moderate to severe non-malignant chronic pain. Up to 80 patients at approximately 15 centers in the US to be enrolled.
- Trial name
- NCT00485225
- Testing
- EN3270
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Durect
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of QVA149 in COPD Patients
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while…
- Trial name
- NCT02487446
- Testing
- QVA149, Umeclidinium/vilanterol
- Where
- 58 sites in United States
- Volunteers
- 357 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease
This study assessed the efficacy and safety of indacaterol (150 µg once daily [od]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease…
- Trial name
- INTRUST2 (NCT00877383)
- Testing
- Indacaterol 150 μg, Tiotropium 18 μg
- Where
- 176 sites in United States, Canada and 7 more
- Volunteers
- 1,142 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease COPD
Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871
This is a study to evaluate the effects of AZD8871 in patients with COPD. Adult male or female patients with moderate to severe COPD, who agree to be in this study, will receive 3 treatments, i.e.
- Trial name
- NCT02971293
- Testing
- AZD8871 100 µg, AZD8871 600 µg
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease: COPD
Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.
The study purpose is to evaluate the effect of QAB149 NVA237 vs. QAB149 on static lung hyperinflation.
- Trial name
- SYNERGY (NCT01699685)
- Testing
- QAB149, NVA237
- Where
- 11 sites in Switzerland
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale
To demonstrate the efficacy of inhaled tiotropium + olodaterol via Respimat® on lung function in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) with optimal and sub-optimal Peak Inspiratory Flow…
- Trial name
- NCT04223843
- Testing
- Tiotropium + olodaterol
- Where
- 26 sites in United States, Germany
- Volunteers
- 213 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to further figure out differences of glycopyrronium bromide compared to tiotropium in early bronchodilation measured by a comprehensive assessment of lung function that includes hyperinflation and…
- Trial name
- FAST (NCT01922271)
- Testing
- NVA237, Tiotropium, Salbutamol
- Where
- 14 sites in Germany
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
This study was conducted to provide detailed information on the efficacy of indacaterol in terms of its effect on spirometry assessed forced expiratory volume in 1 second (FEV1) over a 24 hour time period.
- Trial name
- NCT00622635
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 14 sites in United States, Belgium and 1 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
The purpose of the study is to evaluate the effect of CNTO6785 compared with placebo in participants with moderate to severe Chronic Obstructive Pulmonary Disease.
- Trial name
- NCT01966549
- Testing
- CNTO 6785
- Where
- 44 sites in Czechia, Germany and 6 more
- Volunteers
- 187 people
- Sponsor
- Janssen Research & Development, LLC